Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents.
Rha SW, Kuchulakanti PK, Pakala R, Cheneau E, Pinnow E, Gebreeyesus A, Aggrey G, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Rha SW, et al. Among authors: kent km. Cardiovasc Radiat Med. 2004 Apr-Jun;5(2):64-70. doi: 10.1016/j.carrad.2004.06.003. Cardiovasc Radiat Med. 2004. PMID: 15464942
Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention.
Wolfram R, Leborgne L, Cheneau E, Pinnow EE, Canos DA, Hellinga D, Satler LF, Pichard AD, Kent KM, Waksman R. Wolfram R, et al. Among authors: kent km. Am J Cardiol. 2003 Nov 1;92(9):1080-3. doi: 10.1016/j.amjcard.2003.06.004. Am J Cardiol. 2003. PMID: 14583359
Impact of major side branch on periprocedural enzyme elevation and long-term outcome in patients undergoing percutaneous coronary intervention and brachytherapy for in-stent restenosis.
Kuchulakanti P, Rha SW, Satler LF, Suddath WO, Pichard AD, Kent KM, Pakala R, Canos DA, Pinnow EE, Waksman R. Kuchulakanti P, et al. Among authors: kent km. Am J Cardiol. 2004 Jun 1;93(11):1394-7, A9. doi: 10.1016/j.amjcard.2004.02.038. Am J Cardiol. 2004. PMID: 15165922
Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J; Oral Rapamune to Inhibit Restenosis study. Waksman R, et al. Among authors: kent km. J Am Coll Cardiol. 2004 Oct 6;44(7):1386-92. doi: 10.1016/j.jacc.2004.06.069. J Am Coll Cardiol. 2004. PMID: 15464317 Free article. Clinical Trial.
584 results